(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT WAGVEAIIRILQQLLFIHFRIGCRHSRIGVTQQRRARNGASRS,

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MQPIQIAIAALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS ALVEMGVEMGHHAPWDIDDL, and

(iii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

G1

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAAT NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI LDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLH PVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC; and

(b) detecting the formation of hybrids between said one or more nucleic acid probes and nucleic acid present in said biological sample.

36. (NEW) The method according to claim 35, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

37. (NEW) An *in vitro* diagnostic method for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(a) contacting said biological sample with one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT WAGVEAIIRILQQLLFIHFRIGCRHSRIGVTQQRRARNGASRS and

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

G1

MQPIQIAIAALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS ALVEMGVEMGHHAPWDIDDL; and

(b) detecting the formation of hybrids between said one or more nucleic acid probes and nucleic acid present in said biological sample.

38. (NEW) The method according to claim 37, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

39. (NEW) An *in vitro* diagnostic method for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

(a) contacting said biological sample with one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

MQPIQIAIAALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS ALVEMGVEMGHHAPWDIDDL and

(ii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAAT NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI LDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLH PVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC; and

G1

(b) detecting the formation of hybrids between said one or more nucleic acid probes and nucleic acid present in said biological sample.

40. (NEW) The method according to claim 39, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

41. (NEW) An *in vitro* diagnostic kit for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

(a) a composition comrising one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT WAGVEAIIRILQQLLFIHFRIGCRHSRIGVTQQRRARNGASRS,

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

MQPIQIAIAALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS ALVEMGVEMGHHAPWDIDDL, and

(iii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAAT NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI LDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLH PVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNC;

(b) reagents for detecting the hybrids; and

(c) a biological reference sample lacking nucleic acid recognized by said nucleic acid probe composition.

41. (NEW) The kit according to claim 41, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

43. (NEW) An *in vitro* diagnostic kit for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

(a) a composition comprising one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-1 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MEQAPEDQGPQREPHNEWTLELLEELKNEAVRHFPRIWLHGLGQHIYETYGDT WAGVEAIIRILQQLLFIHFRIGCRHSRIGVTQQRRARNGASRS and

FINNEGAN HENDERSON FARABOW GARRETT & DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

(ii) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MQPIQIAIAALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS ALVEMGVEMGHHAPWDIDDL;

(b) reagents for detecting the hybrids; and

(c) a biological reference sample lacking nucleic acid recognized by said nucleic acid probe composition.

G1

44. (NEW) The kit according to claim 43, wherein said probe is labeled with a label selected from the group consisting of a radioactive label, an enzymatic label, and a fluorescent label.

45. (NEW) An *in vitro* diagnostic kit for detecting the presence or absence of nucleic acid of a Human Immunodeficiency Virus Type 1 (HIV-1) in a biological sample comprising:

(a) a composition comprising one or more nucleic acid probes comprising

(i) a nucleic acid of ORF-4 of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MQPIQIAIAALVVAIIIAIVVWSIVIIEYRKILRQRKIDRLIDRLIERAEDSGNESEGEIS ALVEMGVEMGHHAPWDIDDL and

(ii) a nucleic acid of ORF-R of Human Immunodeficiency Virus Type 1 (HIV-1) encoding the amino acid sequence:

MGGKWSKSSVVGWPTVRERMRRAEPAADGVGAASRDLEKHGAITSSNTAAT NAACAWLEAQEEEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDI

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com